Mallinckrodt plc announced that, following an extensive search, Bryan Reasons has been appointed Chief Financial Officer (CFO), effective immediately. Mr. Reasons will join Mallinckrodt's Executive Committee, the company's senior leadership group, and report directly to President and Chief Executive Officer, Mark Trudeau. George Kegler, who has served as interim CFO of Mallinckrodt, will stay on for a transitional period to ensure a smooth transfer of responsibilities prior to retiring from the company.

Mr. Reasons brings broad financial leadership experience to Mallinckrodt, which he gained in publicly traded pharmaceutical companies known for their success in research, development and commercialization of branded drugs. Serving as Senior Vice President and Chief Financial Officer for six years at Impax Laboratories, Mr. Reasons was instrumental in the company's 2018 combination with Amneal Pharmaceuticals Inc. Mr. Reasons also serves as an independent board director and audit committee chair for both Aclaris Therapeutics Inc. and Recro Pharma Inc.